The Nabriva Therapeutics (NASDAQ:NBRV) stock is soaring this morning and has already clocked gains of 43% this morning, but now cooled off to 11% gains.
The rally in the stock has possibly been triggered by the announcement yesterday that the antibiotic lefamulin developed by Nabriva in collaboration with Sinovant Sciences managed to hit the primary endpoint in the Phase 3 trial of the product. In addition to that, it was also discovered that the antibiotic was not inferior to moxifloxacin either. After the news broke, the stock had rallied strongly on Tuesday as well.
The company had enrolled a total of 125 patients in this particular study. All the patients were suffering from bacterial pneumonia that had spread in the community. In this regard, it should be noted that the rights for selling the product in the Greater Chine region is going to be held by Sunitomo Pharmaceuticals. It could be a good idea from investors to start tracking the Nabriva stock.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.